4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-25-000045
SVP, GEN COUNSEL & CORP SEC sold 5,000 shares at an average $70.74 ($353,699)
- SVP, GEN COUNSEL & CORP SEC acquired 5,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-03-05 | Option exercise 10b5-1 | +5,000 | $21.41 | $107,050 | 46,620 | D |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-03-05 | Sale 10b5-1 | −2,621 | $70.39 | $184,487 | 43,999 | D |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-03-05 | Sale 10b5-1 | −2,267 | $71.07 | $161,107 | 41,732 | D |
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-03-05 | Sale 10b5-1 | −112 | $72.37 | $8,105 | 41,620 | D |
| Derivatives | |||||||
| Eydelman Mikhail SVP, GEN COUNSEL & CORP SEC | 2025-03-05 | Option exercise · Stock Option (right to buy) 10b5-1 | −5,000 | 144,497 | D | ||
| Open-market sales · 5,000 sh · avg $70.74 · $353,699 | |||||||
Loading xslF345X05/wk-form4_1741383777.xml…